XENE — Xenon Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $2.88bn
- $2.25bn
- 50
- 23
- 65
- 43
Annual income statement for Xenon Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 32.2 | 18.4 | 9.43 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 64.5 | 97.4 | 139 | 214 | 279 |
| Operating Profit | -32.3 | -79 | -129 | -214 | -279 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -29.1 | -78.9 | -125 | -183 | -238 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -28.8 | -78.9 | -125 | -182 | -234 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -28.8 | -78.9 | -125 | -182 | -234 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -28 | -77.1 | -125 | -182 | -234 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.792 | -1.77 | -2.06 | -2.73 | -3.01 |